Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex Mucocutaneous Infections and the Prevention of Recurrences: A Pilot Study

Tina A Kituashvili, Vakhtang G Kvirkvelia, George G Galdava, Nino G Archvadze, Tina A Kituashvili, Vakhtang G Kvirkvelia, George G Galdava, Nino G Archvadze

Abstract

Background: Previous in vitro and in vivo studies indicated that walnut extract has a therapeutic effect on herpes simplex infections. This study aimed to evaluate the efficacy and tolerance of Lazolex® Gel (Iveriapharma, Tbilisi, Georgia), an emollient gel to treat mucocutaneous lesions caused by herpes simplex virus.

Methods: A single-center, single-arm, open-label, phase II clinical trial was conducted with 30 patients divided into two groups: 15 patients with herpes simplex virus type 1 (HSV-1) infections and 15 with herpes simplex virus type 2 (HSV-2). All received topical treatment with Lazolex® Gel four times a day for 10 days. The efficacy and tolerance of the treatment were evaluated on day 10 and day 20 of the study. Recurrence rates were also evaluated both prior to treatment with Lazolex® and over a 4-year follow-up period subsequent to treatment.

Results: The median effective time to resolution of symptoms (itching, burning, and pain) was 1.97 days in the HSV-1 group and 3.11 days in the HSV-2 group. The median effective time for vesicles and erosion to disappear was 3.64 days in the HSV-1 group and 3.88 days for the HSV-2 group. Finally, the median effective time for inflammatory signs to disappear was 5.70 and 4.32 days, respectively. Following treatment with Lazolex® Gel, the frequency of outbreaks decreased from a median of 2.00 and 1.00 times per year in the HSV-1 and HSV-2 cohorts to 0.25 and 0.00 (p=0.001 and p=0.003), respectively.

Conclusions: Topical treatment with Lazolex® Gel applied to lesions four times a day for 10 days was shown to be effective and safe in the treatment of herpes simplex mucocutaneous infections and dramatically reduced the rate of recurrence. Clinical trial was approved by Drug Agency of Ministry of Labour, Health and Social Affairs of Georgia, registration # DA Nº CT-000032, date of approval 01.10.2007.

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Copyright © 2022 Tina A. Kituashvili et al.

Figures

Figure 1
Figure 1
Evolution of the lesion stages during the treatment period of the study for the HSV-1 group (herpes labialis). The chart shows the proportion of patients with a corresponding type of lesion over a period of 20 days. ∗Crust stage includes beginning of crust formation to the crust falling off.
Figure 2
Figure 2
Evolution of the lesion stages during the treatment period of the study for the HSV-2 group (genital herpes). The chart shows the proportion of patients with a corresponding type of lesion over a period of 20 days. ∗Crust stage includes beginning of crust formation to the crust falling off.
Figure 3
Figure 3
Visual chart for herpes labialis progression in a 27-year-old female infected with HSV-1.
Figure 4
Figure 4
Visual chart for genital herpes progression. (a) 49-year-old male infected with HSV-2. (b) 46-year-old female infected with HSV-2.

References

    1. Álvarez D. M., Castillo E., Duarte L. F., et al. Current antivirals and novel botanical molecules interfering with herpes simplex virus infection. Frontiers in Microbiology . 2020;11:p. 139. doi: 10.3389/fmicb.2020.00139.
    1. Cole S. Herpes simplex virus. Nursing Clinics of North America . 2020;55(3):337–345. doi: 10.1016/j.cnur.2020.05.004.
    1. James C., Harfouche M., Welton N. J., et al. Herpes simplex virus: global infection prevalence and incidence estimates. Bulletin of the World Health Organization . 2016;98(5):315–329. doi: 10.2471/blt.19.237149.
    1. Petti S., Lodi G. The controversial natural history of oral herpes simplex virus type 1 infection. Oral Diseases . 2019;25(8):1850–1865. doi: 10.1111/odi.13234.
    1. Clebak K. T., Malone M. A. Skin infections. Primary Care: Clinics in Office Practice . 2018;45(3):433–454. doi: 10.1016/j.pop.2018.05.004.
    1. Banerjee A., Kulkarni S., Mukherjee A. Herpes simplex virus: the hostile guest that takes over your home. Frontiers in Microbiology . 2020;11:p. 733. doi: 10.3389/fmicb.2020.00733.
    1. Whitley R., Baines J. Clinical management of herpes simplex virus infections: past, present, and future. F1000Research . 2018;7:p. 1726. doi: 10.12688/f1000research.16157.1.
    1. Schnitzler P. Essential oils for the treatment of herpes simplex virus infections. Chemotherapy . 2019;64(1):1–7. doi: 10.1159/000501062.
    1. Crimi S., Fiorillo L., Bianchi A., et al. Herpes virus, oral clinical signs and QoL: systematic review of recent data. Viruses . 2019;11(5):p. 463. doi: 10.3390/v11050463.
    1. Li W., Wang X. H., Luo Z., et al. Traditional Chinese medicine as a potential source for HSV-1 therapy by acting on virus or the susceptibility of host. IJMS . 2018;19(10):p. 3266. doi: 10.3390/ijms19103266.
    1. Rosa M. I. D., Souza S. L., Farias B. F. D., Pires P. D., Dondossola E. R., Reis M. E. F. D. Efficacy of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of herpes labialis: a systematic review. Anais da Academia Brasileira de Ciencias . 2015;87:1415–1420. doi: 10.1590/0001-3765201520140701.
    1. Annunziata G., Maisto M., Schisano C., et al. Resveratrol as a novel anti-herpes simplex virus nutraceutical agent: an overview. Viruses . 2018;10(9):p. 473. doi: 10.3390/v10090473.
    1. Gnann J. W., Whitley R. J. Genital herpes. New England Journal of Medicine . 2016;375(7):666–674. doi: 10.1056/nejmcp1603178.
    1. De S. K., Hart J. C. L., Breuer J. Herpes simplex virus and varicella zoster virus: recent advances in therapy. Current Opinion in Infectious Diseases . 2015;28(6):589–595. doi: 10.1097/qco.0000000000000211.
    1. Hassan S. T. S., Masarčíková R., Berchová K. Bioactive natural products with anti-herpes simplex virus properties. Journal of Pharmacy and Pharmacology . 2015;67(10):1325–1336. doi: 10.1111/jphp.12436.
    1. Zhao M., Zheng R., Jiang J., et al. Topical lipophilic epigallocatechin-3-gallate on herpes labialis: a phase II clinical trial of AverTeaX formula. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology . 2015;120(6):717–724. doi: 10.1016/j.oooo.2015.08.018.
    1. Cagno V., Sgorbini B., Sanna C., et al. In vitro anti-herpes simplex virus-2 activity of Salvia desoleana Atzei & V. Picci essential oil. PLoS ONE . 2017;12(2) doi: 10.1371/journal.pone.0172322.e0172322
    1. Rechenchoski D. Z., Agostinho K. F., Faccin-Galhardi L. C., et al. Mangiferin: a promising natural xanthone from Mangifera indica for the control of acyclovir—resistant herpes simplex virus 1 infection. Bioorganic & Medicinal Chemistry . 2020;28(4) doi: 10.1016/j.bmc.2020.115304.115304
    1. Gogotishvili M., Abashidze N., Korsantia N., Korsantia N. Immunomodulatory and clinical effectivity of the drug «Lazolex» in treatment of recurrent aphthous stomatitis (RAS) Journal of Experimental and Clinical Medicine Georgia . 2021;3(1)
    1. Gogotishvili M., Abashidze N., Korsantia B. Study of antiviral and immunecorrective effects of Lazolex in patients with recurrent herpetic stomatitis. Georgian Medical News . 2020;307:73–78.
    1. Julious S. A. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics . 2005;4(4):287–291. doi: 10.1002/pst.185.
    1. Herpes M.. Simplex virus: drug resistance and new treatment options using natural products (Review) 2008. .
    1. Sounouvou H. T., Lechanteur A., Piel G., Evrard B. Silicones in dermatological topical drug formulation: overview and advances. International Journal of Pharmaceutics . 2022;625 doi: 10.1016/j.ijpharm.2022.122111.122111
    1. Benedetto A. V. What’s new in cosmetic dermatology. Dermatologic Clinics . 2019;37(1):117–128. doi: 10.1016/j.det.2018.08.002.
    1. Aliyar H., Schalau G. Recent developments in silicones for topical and transdermal drug delivery. Therapeutic Delivery . 2015;6(7):827–839. doi: 10.4155/tde.15.39.
    1. Allen Loyd V. Basics of compounding: compounding with silicones. IJPC . 2015;19(3)
    1. Meaume S., Le Pillouer-Prost A., Richert B., Roseeuw D., Vadoud J. Management of scars: updated practical guidelines and use of silicones. European Journal of Dermatology . 2014;24(4):435–443. doi: 10.1684/ejd.2014.2356.
    1. Angra K., Lipp M. B., Sekhon S., Wu D. C., Goldman M. P. Review of post-laser-resurfacing topical agents for improved healing and cosmesis. Journal of Clinical and Aesthetic Dermatology . 2021;14(8):24–32.
    1. Rodríguez-Archilla A., Raissouni T. Randomized clinical trial of the effectiveness of complementary therapies for recurrent aphthous stomatitis. Medicina Clínica . 2017;149(2):55–60. doi: 10.1016/j.medcle.2017.06.014.
    1. Croitoru A., Ficai D., Craciun L., Ficai A., Andronescu E. Evaluation and exploitation of bioactive compounds of walnut, juglans regia. CPD . 2019;25(2):119–131. doi: 10.2174/1381612825666190329150825.
    1. Cheraghali F., Shojaee-aliabadi S., Hosseini S., et al. Characterization of microcapsule containing walnut (Juglans regia L. green husk extract as preventive antioxidant and antimicrobial agent. International Journal of Preventive Medicine . 2018;9(1):p. 101. doi: 10.4103/ijpvm.ijpvm_308_18.
    1. Soto-Madrid D., Gutiérrez-Cutiño M., Pozo-Martínez J., Zúñiga-López M. C., Olea-Azar C., Matiacevich S. Dependence of the ripeness stage on the antioxidant and antimicrobial properties of walnut (juglans regia L.) green husk extracts from industrial by-products. Molecules . 2021;26(10):p. 2878. doi: 10.3390/molecules26102878.
    1. Boes H., Goulioumis V., Wechsler A., Zimmer S., Bizhang M. Clinical study on the effectiveness of three products in the treatment of herpes simplex labialis. Scientific Reports . 2020;10(1):p. 6465. doi: 10.1038/s41598-020-63530-6.
    1. Hoffmann J., Gendrisch F., Schempp C. M., Wölfle U. New herbal biomedicines for the topical treatment of dermatological disorders. Biomedicines . 2020;8(2):p. 27. doi: 10.3390/biomedicines8020027.
    1. Koytchev R., Alken R. G., Dundarov S. Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis. Phytomedicine . 1999;6(4):225–230. doi: 10.1016/s0944-7113(99)80013-0.
    1. Saller R., Büechi S., Meyrat R., Schmidhauser C. Combined herbal preparation for topical treatment of herpes labialis. Complement Med Res . 2001;8(6):373–382. doi: 10.1159/000057255.
    1. Semprini A., Singer J., Braithwaite I., et al. Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: a randomised controlled trial. BMJ Open . 2019;9(5) doi: 10.1136/bmjopen-2018-026201.e026201
    1. Leung A. K. C., Barankin B. Herpes labialis: an update. Recent Patents on Inflammation & Allergy Drug Discovery . 2017;11(2):107–113. doi: 10.2174/1872213x11666171003151717.
    1. Xia F., Fuhlbrigge M., Dommasch E., Joyce C., Mostaghimi A. Cost of routine herpes simplex virus infection visits to U.S. Emergency departments 2006-2013. West . 2018;19(4):689–692. doi: 10.5811/westjem.2018.3.37543.
    1. Skulason S., Holbrook W. P., Thormar H., Gunnarsson G. B., Kristmundsdottir T. A study of the clinical activity of a gel combining monocaprin and doxycycline: a novel treatment for herpes labialis: clinical trial of a novel treatment for herpes labialis. Journal of Oral Pathology & Medicine . 2012;41(1):61–67. doi: 10.1111/j.1600-0714.2011.01037.x.
    1. Gaby A. R. Natural remedies for herpes simplex. Alternative Medicine Review . 2006;11(2):93–101.
    1. Gogotishvili M. T., Abashidze N. O., Iverieli M. B., Gogishvili X. B., Gogebashvili N. G. The use of Lazolex during complex treatment of chronic recurrent aphthous stomatitis. Tbilisi State Medical University Collection of Scientific Works . 2014;48

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir